Novartis's Rhapsido: A Breakthrough for Millions with Chronic Hives

BASEL, Switzerland – June 12, 2026 – In a move poised to reshape the therapeutic landscape for a debilitating skin condition, Novartis today unveiled pivotal Phase III trial data for its oral drug, Rhapsido® (remibrutinib). The results, presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, position Rhapsido as the first-ever treatment to demonstrate clear efficacy for chronic inducible urticaria (CIndU), a condition affecting an estimated 29 million people worldwide.

The landmark RemIND trial data shows that Rhapsido not only met its primary endpoints but also provided statistically significant and clinically meaningful symptom relief for patients whose lives are dictated by unpredictable and painful hives. For a patient population with no approved targeted therapies and limited recourse beyond often-ineffective antihistamines, this development represents a significant strategic and medical victory.

An Answer for an Invisible Burden

Chronic inducible urticaria is a relentless condition where common environmental factors trigger an inflammatory response. For those affected, everyday life is a minefield of potential triggers: a light scratch can cause raised welts (symptomatic dermographism), a cold breeze can lead to painful swelling (cold urticaria), and even exercise or a hot shower can provoke an outbreak of itchy hives (cholinergic urticaria). Unlike chronic spontaneous urticaria (CSU), where hives appear without a known cause, CIndU’s triggers are specific, yet often unavoidable.

The burden is immense. Over half of the 29 million people living with CIndU find little to no relief from standard treatments like H1-antihistamines, even at up to four times the standard dose. This leaves them in a cycle of symptom management that profoundly impairs their quality of life.

“Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” explained Prof. Dr. med. Martin Metz of Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.”

The Science of Silencing the Itch

The success of Rhapsido lies in its precision. As a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor, it targets the underlying cellular mechanics of the allergic response. BTK is a critical enzyme within mast cells—the immune system’s first responders in an allergic reaction. When activated, BTK signals these cells to degranulate, releasing a flood of histamine and other inflammatory mediators that cause the characteristic hives and itching of urticaria.

Rhapsido works by entering the mast cell and binding to BTK, effectively turning off the switch that triggers this inflammatory cascade. This targeted mechanism of action directly addresses the root cause of symptoms, a stark contrast to antihistamines which only attempt to block the effects of histamine after it has already been released.

The RemIND trial results underscore the power of this approach. Across the three most common CIndU subtypes, Rhapsido demonstrated superior efficacy over placebo at 12 weeks:
* Cold Urticaria: 56.3% of patients on Rhapsido achieved a complete response, compared to just 14.6% on placebo.
* Symptomatic Dermographism: 29.3% of Rhapsido patients had a complete response, versus 14.0% for placebo.
* Cholinergic Urticaria: 29.3% of patients taking Rhapsido saw a complete response, compared to 15.8% in the placebo group.

Crucially, the treatment showed a favorable safety profile consistent with its performance in previous trials for CSU. Novartis reported no observed liver safety concerns, a critical point of differentiation as liver toxicity has been a hurdle for other systemic therapies and some BTK inhibitors in development for other diseases. This clean safety profile, which does not require routine lab monitoring for its approved CSU indication, could significantly lower the barrier to adoption for both physicians and patients.

A Strategic Win in Novartis's Immunology Playbook

From a strategic perspective, Rhapsido's success is a masterstroke for Novartis. By targeting a well-defined condition with a high unmet need and no approved targeted competitors, the company is poised to establish a first-mover advantage in a substantial market. The drug's oral, twice-daily formulation offers a significant convenience benefit over injectable biologics like omalizumab, which is sometimes used off-label for CIndU but requires administration in a clinical setting.

This new indication builds upon Rhapsido's existing approvals for chronic spontaneous urticaria in the U.S., EU, and other major markets, expanding its footprint and cementing its status as a cornerstone of Novartis's burgeoning immunology franchise. The company has already acted on this momentum, submitting a supplemental New Drug Application (sNDA) to the U.S. FDA for the symptomatic dermographism subtype, the most common form of CIndU. Further global filings are planned to continue throughout 2026, signaling a rapid push toward commercialization.

“Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head of Immunology Development at Novartis. “The CIndU data... demonstrate Novartis’ commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.”

The Road Ahead: A Broader Horizon

The potential for remibrutinib does not stop with urticaria. Its targeted action on the BTK pathway has implications for a range of other immune-mediated conditions where mast cells and B-cells play a pathogenic role. Novartis is actively investigating the molecule in clinical trials for hidradenitis suppurativa (HS), food allergies, and even multiple sclerosis (MS), a condition in its neuroscience portfolio.

This pipeline-in-a-product potential transforms remibrutinib from a single-indication treatment into a strategic asset with franchise-building capabilities. Its success in CIndU serves as powerful validation of its underlying scientific platform and Novartis's broader strategy of pursuing deep, disease-modifying therapies. For the millions of patients whose lives are constrained by chronic conditions, this approach offers not just symptom relief, but the prospect of reclaiming control.